As the chief scientific officer, Romanos has led the formation of the company and the development of its proprietary antibody fragment technologies.
Crescendo chairman Clive Dix said that they have seen significant advances in the technology platform and with Mike now taking on the CEO position Crescendo will deliver real value from its proprietary technology platforms.
Crescendo claims that during these time, the company has made significant progress in the establishment of its team and its technology platforms.